Eterna Therapeutics Stock (NASDAQ:ERNA)
Previous Close
$0.69
52W Range
$0.65 - $2.63
50D Avg
$1.11
200D Avg
$1.72
Market Cap
$36.22M
Avg Vol (3M)
$56.49K
Beta
7.77
Div Yield
-
ERNA Company Profile
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
ERNA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ZVSA | ZyVersa Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| VECT | VectivBio Holding AG |
| TCRX | TScan Therapeutics, Inc. |
| APLS | Apellis Pharmaceuticals, Inc. |
| RCUS | Arcus Biosciences, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| PHIO | Phio Pharmaceuticals Corp. |
| REVB | Revelation Biosciences, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| RNAZ | TransCode Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| ANNX | Annexon, Inc. |
| IMMX | Immix Biopharma, Inc. |
| ITOS | iTeos Therapeutics, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| GPCR | Structure Therapeutics Inc. |
| UNCY | Unicycive Therapeutics, Inc. |
| ZURA | Zura Bio Limited |
| PALI | Palisade Bio, Inc. |